Abbott Laboratories (NYSE:ABT), engages in the discovery, development, manufacture, and sale of health care products worldwide, is planned to announce its fiscal second quarter 2012 results on July 18, before the market opens.
The median forecasts of analysts are for profit of $1.21 a share, an increase of 8% from the Corporations actual earnings for the similar quarter in previous year. The median forecast is the same as three months prior. It has plunged from $1.22 during the previous month. Analysts are anticipating profit to climb by 8.1% evaluated against previous year’s $5.05.
The corporation has surpassed forecasts the previous four quarters and is coming off a quarter where it beat estimates by 3 cents, announcing a net income of $1.03 a share against a average forecast of profit of $1 a share.
Shifting readers focus to broader market, let’s consider market performance of other stocks that significantly affect same sector. Pfizer Inc (NYSE:PFE) rose +0.62% to settle at $22.81, Sanofi SA (ADR) (NYSE:SNY) moved up +0.79% to end at $37.10 while AstraZeneca plc (ADR) (NYSE:AZN) jumped +1.56% to finish on Friday at $45.71.
Abbott Laboratories (NYSE:ABT) last session volume of 4.64 million shares was higher than its average volume of 7.72 million shares. The stock after opening at $65.24 hit high price of $65.50 and then closed at $65.45 by scoring +0.49%.
ABT generated revenue of 39.27 billion in the following twelve months and earned $5.11 billion. The Company showed a positive 13.01% in the net profit margin and as well as in its operating margin which remained 15.35%. Company’s annual sales growth for the past five year was 11.57%.
The ABT past twelve months price to sales ratio was 2.62 and price to cash ratio remained 10.81. As far as the returns are concern, the ABT return on equity was recorded as 20.39% and increased 11.36% return on investment while its return on asset stayed at 8.23%.
The stock showed weekly upbeat performance of +1.87% which was maintained for the month at +7.24%. Likewise the positive performance for the quarter was recorded as +10.69% and for the year was +27.38% while the YTD performance remained at 19.33%.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL
